ArticleStem cell research & therapy2026
Efficient genome editing in ASC-derived porcine lung organoids via GFP-guided enrichment.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAdult stem cell-derived organoids are invaluable tools for disease modeling and translational medicine owing to their tissue-specific correspondence. However, their complex three-dimensional structure and low genome-editing efficiency have posed significant challenges for functional genetic studies. To address these limitations, this study aimed to establish porcine lung organoid (PLOs) and to develop a robust, high-efficiency genome-editing platform by leveraging the high physiological and anatomical similarity between pigs and humans.
methodsPLOs were derived from lung tissues and characterized by immunofluorescence and immunohistochemistry analysis. To enhance genome-editing efficiency using CRISPR/Cas9 and prime editing, a GFP-guided enrichment strategy was used by co-targeting a GFP transgene and endogenous loci, followed by the selection of GFP-negative organoids. Clonal expansion from single organoids was performed to generate genetically homogenous lines. Genetic modifications were validated through cDNA sequencing and western blot analysis. Structural integrity was assessed using AlphaFold2 modeling, and functional changes were evaluated using the forskolin-induced swelling assay.
resultsThe established PLOs exhibited sustained self-renewal capacity and expression of surfactant protein C alongside both proximal epithelial and mesenchymal markers, reflecting a composite lung organoid identity. GFP-guided enrichment significantly enriched edited cells; the mutation ratio in the GFP-negative group was significantly higher than that in the GFP-positive group. This system successfully generated fully gene-edited clones with high genetic homogeneity, and effectively enriched for precisely edited organoids, even when applying complex modalities such as prime editing.
conclusionsThe PLOs and genome-editing platform developed in this study provide a powerful resource for translational medicine. By enabling precise genetic manipulation in a model that closely mimics human lung physiology, this system offers an essential platform for recapitulating human lung pathologies, studying zoonotic infectious diseases, and validating the efficacy of gene therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.